Machine Learning-Based Risk Stratification for Fistula Formation After Perianal Abscess Drainage
Launched by GUMUSHANE STATE HOSPITAL · Jun 5, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different factors, like the experience of the doctor performing the procedure and the location where the abscess is drained, can affect the chances of developing a fistula (an abnormal connection between the anal canal and the skin) after treating a perianal abscess. Researchers will also use artificial intelligence (AI) to help read MR images, which could help identify if a fistula is developing early on. The study aims to better understand these issues within six months after the drainage procedure.
To participate in this trial, individuals must be at least 18 years old and dealing with their first perianal abscess that requires surgical drainage. However, those with a history of anal fistulas, Crohn's disease, or those on immunosuppressive treatments won’t be eligible. If you join the study, you can expect regular follow-ups over six months to monitor your recovery and any potential complications. This research could lead to better care for patients in the future by identifying risks early on.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18
- • First-time perianal abscess
- • Surgical drainage performed
- Exclusion Criteria:
- • Existing anal fistula history
- • Crohn's disease
- • Immunosuppressive treatment
- • Incomplete 6-month follow-up
About Gumushane State Hospital
Gumushane State Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient care through clinical trials. With a commitment to innovation and excellence, the hospital collaborates with multidisciplinary teams to conduct rigorous studies that contribute to evidence-based medicine. Equipped with state-of-the-art facilities and a diverse patient population, Gumushane State Hospital aims to enhance therapeutic options and optimize treatment outcomes across various medical fields. Its focus on ethical standards and patient safety underscores its role as a trusted sponsor in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported